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Abstract
Patients with polymyalgia rheumatica have been shown to have an
increased risk of peripheral arterial disease on longitudinal follow-
up. Possible explanations for this include premature atherosclerosis
related to chronic inflammation, as with other inflammatory rheuma-
tological conditions. Alternatively, polymyalgia rheumatica can be
associated with vasculitis, even in the absence of clinical giant cell
arteritis, and peripheral vascular disease may represent subclinical
vasculitis. Further work is required to elucidate the reasons for this
increased risk. Currently, it would remain reasonable to
aggressively control modifiable atherosclerotic risk factors.
Introduction
Warrington and colleagues report an increased risk of
peripheral arterial disease (PAD) in patients with polymyalgia
rheumatica (PMR) compared with matched controls [1]. They
found that 38 out of 353 PMR patients developed PAD
versus 28 out of 705 control subjects over a median follow-
up of 11 years (hazard ratio adjusted for conventional cardio-
vascular risk factors = 2.5, 95% confidence interval = 1.53 to
4.08). The same centre previously reported an increased
likelihood of coronary and cerebrovascular disease in PMR
[2]. The authors speculate that possible explanations for this
are premature atherosclerosis related to inflammation, or the
presence of subclinical vasculitis.
Premature atherosclerosis and autoimmune
inflammatory disease
An increased risk of cardiovascular disease is well estab-
lished in inflammatory rheumatic diseases such as systemic
lupus erythematosus and rheumatoid arthritis [3], over and
above the risk explained by conventional cardiovascular risk
factors. This increase appears to be related to chronic
inflammation, with elevated levels of C-reactive protein
associated with increased risk of cardiovascular disease,
including PAD [4]. Atherosclerosis itself can be explained as
an inflammatory process, with proinflammatory cytokines key
in the development of endothelial dysfunction and the
progression of atheromatous lesions.
Homocysteine has been implicated in the development of
atherosclerotic disease in the general population, and in
patients with systemic lupus erythematosus and rheumatoid
arthritis. Levels of homocysteine have also been found to be
elevated in PMR [5].
Although Warrington and colleagues found no correlation
between PAD and PMR-related disease characteristics or the
erythrocyte sedimentation rate at diagnosis, patients with
PMR were at 2.5-fold increased risk even when adjusted for
conventional risk factors for atherosclerosis [1]. This lack of
association may simply reflect the limited statistical power of
the study, which is acknowledged by the authors. Symp-
tomatic PAD was an infrequent occurrence, seen in 38 out of
353 patients with PMR and in 28 out of 705 control patients.
Atheroma mediated by chronic inflammation may still explain
the elevated PAD risk since chronic inflammation in PMR
would not be captured by the erythrocyte sedimentation rate
at diagnosis. A previous study from the Mayo Clinic demon-
strated an association between sustained elevation in the
erythrocyte sedimentation rate (>3 recorded measurements
>60 mm/hour at least 30 days apart) and cardiovascular
death in rheumatoid arthritis. Measures such as this or the
time spent with clinically active disease would better reflect
chronic inflammation [6]. C-reactive protein may be a better
marker of cardiovascular risk in PMR, as this association is
well demonstrated in other chronic diseases, both rheuma-
tological and non-rheumatological.
In the related condition of giant cell arteritis (GCA), increased
cardiovascular mortality was associated with both the erythro-
cyte sedimentation rate and the steroid dose, suggesting
proatherogenic effects of high-dose glucocorticoids and/or
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uncontrolled inflammation [7]. The higher PAD risk in PMR
found by Warrington and colleagues may also be explained
by steroid use, although lower doses and a smaller sample
size may have led to the observed lack of association [1]. This
lower steroid dose may explain why, in a previous study from
the same centre, glucorticoid use was not associated with
increased risk of coronary, peripheral vascular or cerebro-
vascular disease (hazard ratio = 0.58 to 0.85) [8].
Subclinical vasculitis
Arteritis has not been demonstrated in premature cardio-
vascular disease in systemic lupus erythematosus or rheuma-
toid arthritis on postmortem examination [3]. Arteritis remains
a possibility, however, in PMR and GCA. A study of biopsy-
proven GCA demonstrated no increase in carotid intimal
thickness, so atherosclerosis alone does not explain the
increased cardiovascular mortality seen in GCA [9].
Although Warrington and colleagues did not find that the
presence of clinical GCA correlated with PAD, the sample
size was small. Cranial GCA has also been shown to be
negatively associated with large vessel involvement [10].
Moosig and colleagues demonstrated large artery (aortic,
subclavian, and axillary) uptake on positron emission
tomography in 12 out of 13 patients with active PMR, but no
clinical evidence of GCA [11]. Proinflammatory macrophage
and T-cell-derived cytokine mRNA profiles similar to that of
GCA have been found in histologically normal temporal artery
specimens from patients with isolated PMR [12]. Subclinical
ongoing large vessel vasculitis can therefore occur and may
contribute to the increased risk of PAD in isolated PMR.
Conclusions
The interesting findings of Warrington and colleagues add
further weight to the association between vascular disease
and inflammatory rheumatological conditions. In PMR this
possibly relates to inflammation-related atherosclerosis, or to
subclinical arteritis. Further longitudinal observational cohort
studies including structured documentation of disease
activity, cumulative steroid dosages, and C-reactive protein
levels are required to unravel the multiplicity of factors and
interactions that may contribute to adverse vascular events in
this condition.
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